Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The North America viral vector manufacturing market size was valued at USD 4.2 billion in 2023, driven by the increased funding for the development of gene therapies in the region. The market is expected to grow at a CAGR of 7.16% during the forecast period of 2024-2032, with the values likely to rise from USD 4.5 billion in 2024 to USD 7.9 billion by 2032.
In North America, the market is witnessing steady growth driven by the rising demand for gene therapy, vaccines, and other innovative therapeutics to tackle the growing burden of genetic disorders, chronic diseases, and infectious diseases, among others. Viral vectors such as adeno-associated viruses, adenoviruses, and lentiviruses are increasingly employed for gene transfer in gene therapy. The substantial funding for the development of gene therapies is expected to drive the North America viral vector manufacturing market growth in the forecast period. In November 2023 , a study published in Nature estimated the annual spending on gene therapy to be USD 20.4 billion in the United States. This rising investment in the biotechnology sector is likely to boost the market size.
One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players supported by major financial investments. In November 2023 , Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing led by Ampersand Capital Partners which aimed to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to their cell and gene therapy innovators. Such investments are also poised to foster technological innovation and expansion of manufacturing sites and is expected to meet the growing North America viral vector manufacturing market demand.
In September 2023 , Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Situated at Plainville, Massachusetts, the company intended to make use of its 400,000 square feet viral vector manufacturing unit to boost viral vector production along with gene therapy production simultaneously. These initiatives mark as one of the most impactful North America viral vector manufacturing market trends, expected to help in accelerating the development and commercialization of life-saving therapies which will ultimately impact the market dynamics.
Other factors that influence the market share include the advancement in the healthcare infrastructure, increased research efforts aimed at finding novel therapeutics, and the improvement in regulatory reforms.
North America viral vector manufacturing market analysis include a detailed breakup of the market based on the following segments:
Market Breakup | Categories |
Type | Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Others |
Disease | Cancer, Genetic Disorders, Infectious Diseases, Others |
Expression System | Transient, Stable |
Application | Gene Therapy, Vaccinology, Therapeutics Development, Research |
End User | Pharmaceutical and Biotechnology Companies, Research Institutes, CDMO & CROs, Others |
Countries | United States of America, Canada |
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Disease |
|
Breakup by Expression System |
|
Breakup by Application |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 4.2 billion in 2023 driven by the driven by the increased funding for the development of gene therapies in the region.
The market is anticipated to grow at a CAGR of 7.16% during the forecast period of 2024-2032, likely to reach a market value of USD 7.9 billion by 2032.
The growing prevalence of genetic disorders and the rising healthcare expenditure are fuelling the demand for the market.
One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players. In November 2023 , Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing. The funding was intended at strengthening its viral vector manufacturing capabilities as well as enabling better support to their cell and gene therapy innovators.
Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, and retroviral vectors, among others.
Expression systems available in the market include transient and stable.
By disease, the market is divided into cancer, genetic disorders, and infectious diseases, among others.
End users of the market are pharmaceutical and biotechnology companies, research institutes, CDMOs & CROs, among others.
Major applications areas of viral vector manufacturing include gene therapy, vaccinology, therapeutics development, and research.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Charles River Laboratories, Finvector, Kaneka Eurogentec SA, Merck KGaA, UniQure NV, Oxford Biomedica PLC, AstraZeneca, Vibalogics, Sanofi, and F. Hoffmann-La Roche Ltd.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share